参考文献/References:
[1] Carcereny E, Moran T, Capdevila L, et al. The epider -mal growth factor receptor ( EGRF) in lung cancer[ J] .Transl Respir Med,2015,3: 1.
[2 ] Stintzing S. Management of colorectal cancer [ J] .F1000Prime Rep,2014,6: 108.
[3] Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classificationof malignant tumours [ M] . 7th ed. Hoboken:John Wiley &Sons,2009.
[4]支修益,吴一龙,马胜林,等.原发性肺癌诊疗规范(2011年版)[J].中国肺癌杂志,2012,15(12):677-688.
[5] Chen AP, Setser A, Anadkat MJ, et al. Grading derma -tologic adverse events of cancer treatments: the CommonTerminology Criteria for Adverse Events Version 4. 0[ J] . J Am Acad Dermatol,2012,67( 5) : 1025 -1039.
[6] Eisenhauer EA, Therasse P, Bogaerts J, et al. New responseevaluation criteria in solid tumours: revised RECISTguideline( version 1. 1) [ J] . Eur J Cancer, 2009, 45(2) : 228 -247.
[7] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy asfirst - line treatment for patients with advancedEGFR mutation - positive non - small - cell lung cancer (OPTIMAL, CTONG -0802 ) : amulticentre, open - label,randomised, phase 3 study[ J] . Lancet Oncol, 2011, 12(8) : 735 -742.
[8] Reck M, von Pawel J, Zatloukal P, et al. Overall survivalwithcisplatin - gemcitabine and bevacizumab or placebo asfirst - linetherapy for nonsquamous non - small - cell lungcancer: results from arandomized phase Ⅲ trial ( AVAiL) [ J] . Ann Oncol,2010,21( 9) : 1804 -1809.
[9] Pirker R, Pereira J R, Szczesna A, et al. Cetuximab pluschemotherapy in patients with advanced non - small - celllung cancer( FLEX) : an open - label randomised phaseⅢ trial[ J] . Lancet,2009,373( 9674) : 1525 -1531.
[10] Lichtenberger BM, Gerber PA, Holcmann M, et al. Epi- dermal EGFR controls cutaneous host defense and pre -vents inflammation[ J] . Sci Transl Med, 2013, 5 ( 199)
:199ra111.
[11] Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology ofskin toxicity associated with epidermal growth factor re -ceptor ( EGFR ) inhibitors[ J] . Support Care Cancer,2012,20( 5) : 909 -921.
[12] Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clini- cal practice guidelines for the prevention and treatmentofEGFR inhibitor - associated dermatologic toxicities [ J] .Support Care Cancer,2011,19( 8) : 1079 -1095.
[13] Macdonald JB, Macdonald B, Golitz LE, et al. Cutane -ous adverse effects of targeted therapies: Part 1: Inhibi -tors of the cellular membrane[ J] . J Am Acad Dermatol,2015,72( 2) : 203 -218,219 -220.
[14] Curry JL, Torres - Cabala CA, Kim KB, et al. Dermato -logic toxicities to targeted cancer therapy: shared clinicaland histologic adverse skin reactions[ J] . Int J Dermatol,2014,53( 3) : 376 -384.
[15] Sinclair R. Anticipating and managing the cutaneoussideeffects of epidermal growth factor receptor inhibitors[ J] . Asia Pac J Clin Oncol,2014,10 Suppl 1: 11 -17.
[16]孙广仁.中医基础理论[M].北京:中国中医药出版社,2002:74-83.
[17]肖寒,方乃青,申小苏.加减沙参麦冬汤联合化疗治疗Ⅲ?Ⅳ期非小细胞肺癌[J].中国实验方剂学杂志,2011,17(24):203-207.
[18]潘国凤,宋巧玲,吴良村.新加沙参麦冬汤联合放疗治疗中晚期非小细胞肺癌30例临床疗效观察[J].中华中医药杂志,2010,25(6):951-952.
[19]袁国荣,潘智敏.沙参麦冬汤减轻易瑞沙不良反应的临床研究[J].中华中医药学刊,2011,29(4):930-931.
相似文献/References:
[1]王留晏 陈露 张克克.肺癌从脾肾论治体悟[J].陕西中医药大学学报,2019,(01):040.[doi:10.13424/j.cnki.jsctcm.2019.01.014]
[2]李宜鲜 魏华琳??.山豆根乙醇提取物对 Lewis 肺癌小鼠的抗肿瘤作用[J].陕西中医药大学学报,2021,44(03):086.[doi:10.13424/j.cnki.jsctcm.2021.03.019]
[3]王颖 唐晓男 王会宜 崔艳慧 曹飞 康小红.华蟾素胶囊联合吉非替尼对晚期肺癌患者临床疗效及血清miR-221表达的影响[J].陕西中医药大学学报,2021,44(06):084.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
WANG Ying TANG Xiaonan WANG Huiyi CUI Yanhui CAO Fei KANG Xiaohong.Effect of Cinobufagin Capsule Combined withGefitinib on Clinical Efficacy and Serum miR221Expression in Patients with Advanced Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(03):084.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
[4]田王琪 张蔚桐 汪一凡 郭惠 王育伟.中药多糖通过调控肠道菌群干预肺癌的文献研究[J].陕西中医药大学学报,2023,(02):027.[doi:10.13424/j.cnki.jsctcm.2023.02.005
]
TIAN Wangqi ZHANG Weitong WANG Yifan GUO Hui WANG Yuwei TANG Yuping.Research Progress of Chinese Herbal Polysaccharides
Intervening Lung Cancer by Regulating Intestinal Flora[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(03):027.[doi:10.13424/j.cnki.jsctcm.2023.02.005
]